Monday , November 23 2020

AstraZeneca: saracatinib dsign drug orphan



AstraZeneca announced Monday that the US FDA has given orphan drug designation to its saracatinib, a potential drug for the treatment of idiopathic pulmonary fibrosis.

The UK laboratory specifies that drug designation is for products that can treat, diagnose, or prevent rare diseases affecting less than 200,000 people in the United States.

Chronic, progressive, irreversible and usually fatal lung disease affects lung idiopathic fibrosis about 100,000 people in the United States. On average, patients live two to five years after diagnosis.

Copyright (c) 2019 CercleFinance.com. All rights reserved.


Source link